Raia Drogasil S.A (RADLY) Fair Value & Analysis
Healthcare · US · Market cap $5.8B
Raia Drogasil S.A
RADLY · US
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Jul 19, 2026, revised from $2.38 to $2.42 (+1.7%) since Jun 24, 2026. Share price +4.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $2.33 – $5.19 · fair‑value band $1.81 – $3.92 · the $3.53 price screens above the $2.42 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Raia Drogasil S.A (RADLY) currently trades at $3.53, while our model-based Fair Value estimate is $2.42, implying the stock looks roughly 31.4% overvalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Raia Drogasil S.A generated revenue of $45.5B at a net margin of 2.8%. Revenue grew 14.0% year over year. It earns a return on equity of 18.9%. Net debt stands at $8.3B. Fundamentals as of Jul 19, 2026
Our scenario range runs from $1.81 (bear case) to $3.92 (bull case); at $3.53, the current price sits within that range. The share trades about 32% below its 52-week high and 52% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at -31%, RADLY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Raia Drogasil S.A reported revenue of $43.4B in FY2025 versus $24.1B in FY2021, a compound +15.8%/yr. Reported net income was $1.3B in FY2025, compounding +14.0%/yr from FY2021.
Is RADLY fairly valued? → Check now
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.75 | $6.92 | -21% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $29.02 | $34.57 | +19% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
| Corporativo Fragua, S.A. CGSBF | $29.66 | $40.13 | +35% |
| DaShenLin Pharmaceutical Group 603233 | ¥15.87 | ¥26.45 | +67% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.18 | ¥13.89 | +14% |
| Redcare Pharmacy NV SHPPF | $64.80 | $17.64 | -73% |
| MedPlus Health Services Limited MEDPLUS | ₹816.95 | ₹393.38 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Raia Drogasil S.A (RADLY) undervalued?
What is the fair value of RADLY?
What is the quality score of RADLY?
What is the revenue of Raia Drogasil S.A (RADLY)?
What is the net profit margin of RADLY?
Does Raia Drogasil S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Raia Drogasil S.A analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.